Compounds for treatment of complement mediated disorders

US10428095B2 · kind B2 · utility

Assignee

• Achillion Pharmaceuticals, Inc. · US

Inventors

• Jason Allan Wiles · Madison, US
• Avinash Phadke · Branford, US
• Xiangzhu Wang · Madison, US
• Dawei Chen · Middletown, US
• Akihiro Hashimoto · Branford, US
• Venkat Rao Gadhachanda · Hamden, US
• Godwin Pais · Hamden, US
• Qiuping Wang · Bethany, US
• Atul Agarwal · Hamden, US
• Milind Deshpande · Madison, US

Key dates

• Filing date: Oct 1, 2018
• Grant date: Oct 1, 2019
• Expiry date: Oct 1, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.